OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Kantoff on Evolving Role of Docetaxel in Prostate Cancer Treatment

November 18th 2016

Philip W. Kantoff, MD, chairman of Medicine at Memorial Sloan Kettering Cancer Center and a 2014 Giants of Cancer Care winner for Genitourinary Cancer, discusses the role that chemotherapy treatment with docetaxel will continue to have in patients with prostate cancer. Kantoff shared this insight in an interview during the 2016 OncLive State of the Science Summit on Genitourinary Cancers.

Dr. Scher on Predicting Sensitivity to Treatment for mCRPC

November 18th 2016

Howard I. Scher, MD, chief, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, discusses understanding the genetics of patients with metastatic castration-resistant prostate cancer.

Dr. Iyer on Advice for Physicians Using Immunotherapy in Bladder Cancer

November 18th 2016

Gopa Iyer, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses significant points for community oncologists to be aware of when treating patients with bladder cancer with immunotherapy agents.

Dr. Kris on Sequencing Challenges in Lung Cancer

November 17th 2016

Mark G. Kris, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses challenges associated with sequencing in the treatment of patients with lung cancer.

Dr. Borgen on Successful Progress in HER2-Positive Breast Cancer

November 17th 2016

Patrick Borgen, MD, chair, Department of Surgery, director, Breast Center, Maimonides Medical Center, discusses the successful progress seen in the treatment landscape of HER2-positive breast cancer.

Sonja Althammer on Role of CD8 and PD-L1 Biomarkers for Immunotherapy in NSCLC

November 17th 2016

Sonja Althammer, PhD, Team Leader Bioinformatics at Definiens, Munich, Bavaria, Germany, discusses a study looking to define a subgroup of patients with non–small cell lung cancer (NSCLC) who respond well to treatment with the PD-L1 inhibitor durvalumab.

Dr. Suzanne L. Topalian on Immunotherapy Biomarkers in CRC

November 17th 2016

Suzanne L. Topalian, MD, professor of Surgery, Johns Hopkins Medicine, discuses novel immunotherapy biomarkers in colorectal cancer (CRC).

Dr. Goldberg on PD-L1 as a Biomarker in Lung Cancer

November 17th 2016

Sarah B. Goldberg, MD, MPH, assistant professor of Medicine, Yale Cancer Center, discusses the use of PD-L1 as a biomarker in treating patients with lung cancer.

Susan Lutgendorf on Impact of Minimal Support on Patients With Ovarian Cancer

November 16th 2016

Susan Lutgendorf, PhD, professor and Starch Faculty Fellow, Psychological and Brain Sciences, College of Liberal Arts and Sciences, University of Iowa, discusses the impact of lack of support on patients with ovarian cancer. Lutgendorf spoke on this during an interview at the SITC 31st Annual Meeting and Associated Programs.

Dr. Borghaei on the Management of Immune-Related Side Effects in Lung Cancer

November 16th 2016

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the management of slightly rarer side effects that patients with lung cancer can experience when treated with immunotherapy agents.

Lisa Butterfield on SITC Immune Biomarkers Task Force

November 16th 2016

Lisa Butterfield, PhD, professor of Medicine, Surgery and Immunology, director, University of Pittsburgh Cancer Institute Immunologic Monitoring and Cellular Products Laboratory, University of Pittsburgh, discusses the goals of the Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force during an interview at the SITC 31st Annual Meeting and Associated Programs.

Dr. Tripathy on Neoadjuvant Agents for HER2+ Breast Cancer

November 16th 2016

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses agents that are available and in development in the neoadjuvant setting as treatments for patients with HER2-positive breast cancer.

Dr. Michael Birrer on Immunotherapy Potential in Cervical Cancer

November 16th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses recent advancements in cervical cancer.

Dr. Alan P. Venook on Determining Frontline Treatment for mCRC

November 16th 2016

Alan P. Venook, MD, The Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses factors in determining first-line treatment for patients with metastatic colorectal cancer (mCRC).

Dr. Rathkopf on Mitigating AR-Resistance in Prostate Cancer

November 15th 2016

Dana E. Rathkopf, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses mitigating androgen receptor (AR)-resistance in patients with prostate cancer.

Dr. Anders on Systemic Agents for Patients With Breast Cancer and Brain Mets

November 15th 2016

Carey Anders, MD, assistant professor for the Department of Medicine, Division of Hematology and Oncology, at UNC-Chapel Hill, UNC Linebarger Comprehensive Cancer Center, discusses systemic agents available and in development for patients with breast cancer who also have brain metastases.

Dr. Sankhala on the TRC105/Pazopanib Combination in Angiosarcoma

November 12th 2016

Kumar Sankhala, MD, medical director of Clinical Research, Sarcoma Oncology Center, discusses results of a recent trial looking at the combination of endoglin antibody TRC105 and pazopanib in patients with advanced angiosarcoma.

Dr. Vokes on Nivolumab, Pembrolizumab Approvals in Head and Neck Cancer

November 12th 2016

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the FDA approvals of the PD-L1 inhibitors nivolumab (Opdivo) and pembrolizumab (Keytruda) for the treatment of patients with head and neck cancer.

Dr. Bryan Mehlhaff on Advances in mCRPC

November 12th 2016

Bryan Mehlhaff, MD, medical director of research for Oregon Urology Institute, discusses recent advancements in and what he sees on the horizon for metastatic castrate-resistant prostate cancer (mCRPC).

Dr. Dreicer on Combination Trials With Radium-223 in mCRPC

November 12th 2016

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses the potential of combination regimens involving radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).